LAEVOROC ONCOLOGY NEWS

Laevoroc Chemotherapy will develop a new oral gemcitabine prodrug, LR 06B, aiming to make a positive impact on health equity and quality of care for cancer patients around the world...

Laevoroc Oncology Unveils Immunology Subsidiary with CSO Shanta Bantia to Develop PNP Inhibitor for Eradication of Relapsed Leukemia Laevoroc Immunology formed to focus on development of a highly potent Purine...

In Vivo interview with our CEO, Thomas Mehrling, where he presented Laevoroc Oncology’s three-pronged strategy to off-set risk and provide greater choice to future partners in supporting Laevoroc’s development of...